128 related articles for article (PubMed ID: 16402365)
1. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion.
Verhagen PC; van Duijn PW; Hermans KG; Looijenga LH; van Gurp RJ; Stoop H; van der Kwast TH; Trapman J
J Pathol; 2006 Apr; 208(5):699-707. PubMed ID: 16402365
[TBL] [Abstract][Full Text] [Related]
2. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
[TBL] [Abstract][Full Text] [Related]
3. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
4. [Research on the mechanisms of PTEN gene inactivation in ovarian cancer].
Lü QJ; Zhao XD; Song JY; Li XH; Ma Y; Meng H; Jiang WG
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):266-9. PubMed ID: 16181546
[TBL] [Abstract][Full Text] [Related]
5. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
[TBL] [Abstract][Full Text] [Related]
7. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.
Hermans KG; van Alewijk DC; Veltman JA; van Weerden W; van Kessel AG; Trapman J
Genes Chromosomes Cancer; 2004 Mar; 39(3):171-84. PubMed ID: 14732919
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutation of PTEN in bladder carcinoma.
Aveyard JS; Skilleter A; Habuchi T; Knowles MA
Br J Cancer; 1999 May; 80(5-6):904-8. PubMed ID: 10360673
[TBL] [Abstract][Full Text] [Related]
9. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns P; Okami K; Halachmi S; Halachmi N; Esteller M; Herman JG; Jen J; Isaacs WB; Bova GS; Sidransky D
Cancer Res; 1997 Nov; 57(22):4997-5000. PubMed ID: 9371490
[TBL] [Abstract][Full Text] [Related]
10. Is PTEN loss associated with clinical outcome measures in human prostate cancer?
McCall P; Witton CJ; Grimsley S; Nielsen KV; Edwards J
Br J Cancer; 2008 Oct; 99(8):1296-301. PubMed ID: 18854827
[TBL] [Abstract][Full Text] [Related]
11. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.
Freihoff D; Kempe A; Beste B; Wappenschmidt B; Kreyer E; Hayashi Y; Meindl A; Krebs D; Wiestler OD; von Deimling A; Schmutzler RK
Br J Cancer; 1999 Feb; 79(5-6):754-8. PubMed ID: 10070865
[TBL] [Abstract][Full Text] [Related]
12. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.
Yoshimoto M; Ludkovski O; DeGrace D; Williams JL; Evans A; Sircar K; Bismar TA; Nuin P; Squire JA
Genes Chromosomes Cancer; 2012 Feb; 51(2):149-60. PubMed ID: 22045666
[TBL] [Abstract][Full Text] [Related]
13. Analysis of PTEN and the 10q23 region in primary prostate carcinomas.
Feilotter HE; Nagai MA; Boag AH; Eng C; Mulligan LM
Oncogene; 1998 Apr; 16(13):1743-8. PubMed ID: 9582022
[TBL] [Abstract][Full Text] [Related]
14. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Wang SI; Parsons R; Ittmann M
Clin Cancer Res; 1998 Mar; 4(3):811-5. PubMed ID: 9533551
[TBL] [Abstract][Full Text] [Related]
15. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.
Yoshimoto M; Cutz JC; Nuin PA; Joshua AM; Bayani J; Evans AJ; Zielenska M; Squire JA
Cancer Genet Cytogenet; 2006 Sep; 169(2):128-37. PubMed ID: 16938570
[TBL] [Abstract][Full Text] [Related]
16. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
Vlietstra RJ; van Alewijk DC; Hermans KG; van Steenbrugge GJ; Trapman J
Cancer Res; 1998 Jul; 58(13):2720-3. PubMed ID: 9661880
[TBL] [Abstract][Full Text] [Related]
17. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
[TBL] [Abstract][Full Text] [Related]
18. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Yoshimoto M; Cunha IW; Coudry RA; Fonseca FP; Torres CH; Soares FA; Squire JA
Br J Cancer; 2007 Sep; 97(5):678-85. PubMed ID: 17700571
[TBL] [Abstract][Full Text] [Related]
19. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
Lotan TL; Wei W; Ludkovski O; Morais CL; Guedes LB; Jamaspishvili T; Lopez K; Hawley ST; Feng Z; Fazli L; Hurtado-Coll A; McKenney JK; Simko J; Carroll PR; Gleave M; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Lance R; Troyer D; Squire JA
Mod Pathol; 2016 Aug; 29(8):904-14. PubMed ID: 27174589
[TBL] [Abstract][Full Text] [Related]
20. Simple quantitative PCR analysis for allelic Pten loss in tumor progression.
Wu X; Zhu A; Pang X; Xie G; Gu X
Anal Biochem; 2017 Jun; 526():50-57. PubMed ID: 28322802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
